


26. A compound of structural formula I:



or a pharmaceutically acceptable salt thereof, wherein:

V and W are both N, or V and W are both CH;

Z is selected from CH and N, provided that when V and W are CH, then Z is not N;

R<sup>1</sup> is H, C<sub>1-3</sub> alkyl, C<sub>1-3</sub> alkoxy, F, or Cl;

R<sup>2</sup> is S(O)<sub>n</sub> R<sup>6</sup>, COR<sup>6</sup> or CHO, wherein:

n is 0, 1 or 2, and

R<sup>6</sup> is N(R<sup>3</sup>)<sub>2</sub> or C<sub>1-3</sub> alkyl;

R<sup>3</sup> is independently H or C<sub>1-3</sub> alkyl;

Ar is aryl or heteroaryl;

R<sup>4</sup> and R<sup>5</sup> are independently selected from:

(1) hydrogen,

(2) aryl, either unsubstituted or substituted with

(a) halo,

(b) C<sub>1-3</sub> alkoxy,


(c)-N(C<sub>1-3</sub> alkyl)<sub>2</sub>,

(d) C<sub>2-4</sub> alkanoyl, or

(e) aryl,

- (3) nitro,
- (4) C<sub>1-5</sub> alkyl,
- (5) C<sub>1-5</sub> alkoxy,
- (6) hydroxy-C<sub>1-3</sub> alkyl,
- (7) carboxy,
- (8) halo,
- (9) C<sub>1-5</sub> alkylthio,
- (10) C<sub>1-5</sub> ethoxycarbonyl,
- (11) pyridylcarbonyl,
- (12) benzoyl,
- (13) phenyl-C<sub>1-3</sub> alkoxy,
- (14) pyridyl, either unsubstituted or substituted with  
C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkoxy,
- (15) C<sub>3-6</sub> cycloalkyl,
- (16) oxazolyl,
- (17) thiazolyl,
- (18) triazolyl,
- (19) phenoxy, and
- (20) C<sub>2-6</sub> alkanoyl.

27. The compound of Claim 26 wherein Z, V and W are N.
28. The compound of Claim 27 wherein Ar is phenyl, of structural formula  
I(a):




I(a)

or a pharmaceutically acceptable salt thereof.

29. The compound of Claim 28 wherein R<sup>2</sup> is -SO<sub>2</sub>(C<sub>1-3</sub> alkyl) or SO<sub>2</sub>NH<sub>2</sub>.

30. The compound of Claim 29 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C<sub>1-5</sub> alkylpyridyl, benzhydryl, phenyl-C<sub>1-3</sub> alkoxy, NO<sub>2</sub>, C<sub>2-4</sub> alkanoyl, halo, C<sub>1-5</sub> alkoxy, C<sub>1-3</sub> alkoxycarbonyl, C<sub>1-5</sub> alkylthio, triazolyl, carboxy, hydrogen, C<sub>1-5</sub> alkyl, pyridylcarboxy, and C<sub>1-3</sub> alkoxyphenyl.

31. The compound of Claim 30 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)


or a pharmaceutically acceptable salt thereof.

32. The compound of Claim 31 wherein R<sup>2</sup> is -SO<sub>2</sub>(C<sub>1-3</sub> alkyl) or SO<sub>2</sub>NH<sub>2</sub>.

33. The compound of Claim 32 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C<sub>1-5</sub> alkylpyridyl, benzhydryl, phenyl-C<sub>1-3</sub> alkoxy, NO<sub>2</sub>, C<sub>2-4</sub> alkanoyl, halo, C<sub>1-5</sub> alkoxy, C<sub>1-3</sub> alkoxycarbonyl, C<sub>1-5</sub> alkylthio, triazolyl, carboxy, hydrogen, C<sub>1-5</sub> alkyl, pyridylcarboxy, and C<sub>1-3</sub> alkoxyphenyl.

34. The compound of Claim 26 wherein Z is CH and both V and W are N.

35. The compound of Claim 34 wherein Ar is phenyl, of structural formula I(a):




I(a)

or a pharmaceutically acceptable salt thereof.

36. The compound of Claim 35 wherein R<sup>2</sup> is -SO<sub>2</sub>(C<sub>1-3</sub> alkyl) or SO<sub>2</sub>NH<sub>2</sub>.

37. The compound of Claim 36 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C<sub>1-5</sub> alkylpyridyl, benzhydryl, phenyl-C<sub>1-3</sub> alkoxy, NO<sub>2</sub>, C<sub>2-4</sub> alkanoyl, halo, C<sub>1-5</sub> alkoxy, C<sub>1-3</sub> alkoxycarbonyl, C<sub>1-5</sub> alkylthio, triazolyl, carboxy, hydrogen, C<sub>1-5</sub> alkyl, pyridylcarboxy, and C<sub>1-3</sub> alkoxyphenyl.

38. The compound of Claim 37 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)


or a pharmaceutically acceptable salt thereof.

39. The compound of Claim 38 wherein R<sup>2</sup> is -SO<sub>2</sub>(C<sub>1-3</sub> alkyl) or SO<sub>2</sub>NH<sub>2</sub>.

40. The compound of Claim 39 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C<sub>1-5</sub> alkylpyridyl, benzhydryl, phenyl-C<sub>1-3</sub> alkoxy, NO<sub>2</sub>, C<sub>2-4</sub> alkanoyl, halo, C<sub>1-5</sub> alkoxy, C<sub>1-3</sub> alkoxy carbonyl, C<sub>1-5</sub> alkylthio, triazolyl, carboxy, hydrogen, C<sub>1-5</sub> alkyl, pyridylcarboxy, and C<sub>1-3</sub> alkoxyphenyl.

41. The compound of Claim 26 wherein Z, V and W are CH.

42. The compound of Claim 41 wherein Ar is phenyl, of structural formula I(a):




I(a)

or a pharmaceutically acceptable salt thereof.

43. The compound of Claim 42 wherein R<sup>2</sup> is -SO<sub>2</sub>(C<sub>1-3</sub> alkyl) or SO<sub>2</sub>NH<sub>2</sub>.

44. The compound of Claim 43 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C<sub>1-5</sub> alkylpyridyl, benzhydryl, phenyl-C<sub>1-3</sub> alkoxy, NO<sub>2</sub>, C<sub>2-4</sub> alkanoyl, halo, C<sub>1-5</sub> alkoxy, C<sub>1-3</sub> alkoxycarbonyl, C<sub>1-5</sub> alkylthio, triazolyl, carboxy, hydrogen, C<sub>1-5</sub> alkyl, pyridylcarboxy, and C<sub>1-3</sub> alkoxyphenyl.

45. The compound of Claim 44 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):




I(b)

or a pharmaceutically acceptable salt thereof.

46. The compound of Claim 45 wherein R<sup>2</sup> is -SO<sub>2</sub>(C<sub>1-3</sub> alkyl) or SO<sub>2</sub>NH<sub>2</sub>.

47. The compound of Claim 46 wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C<sub>1-5</sub> alkylpyridyl, benzhydryl, phenyl-C<sub>1-3</sub> alkoxy, NO<sub>2</sub>, C<sub>2-4</sub> alkanoyl, halo, C<sub>1-5</sub> alkoxy, C<sub>1-3</sub> alkoxycarbonyl, C<sub>1-5</sub> alkylthio, triazolyl, carboxy, hydrogen, C<sub>1-5</sub> alkyl, pyridylcarboxy, and C<sub>1-3</sub> alkoxyphenyl.

48. The compound of Claim 26 wherein R<sup>2</sup> is -COR<sup>6</sup> of structural formula I(d):







I(d)



or a pharmaceutically acceptable salt thereof.

49. The compound of Claim 48 or a pharmaceutically acceptable salt thereof selected from those depicted in the following Table:

<u>R<sup>6</sup></u>	<u></u>
-CH <sub>3</sub>	
-CH <sub>3</sub>	
-CH <sub>3</sub>	

50. A method of treating Y5 receptor mediated disease selected from the group consisting of obesity, anorexia nervosa, bulimia nervosa, diabetes, hypertension, hyperlipemia, hypercholesterolemia, congestive heart failure, renal dysfunction, sexual/reproductive disorders, depression, anxiety, epileptic seizure, memory loss, migraine, cerebral hemorrhage, nasal congestion, gastrointestinal disorders, and arthritis, which comprises administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Claim 26 that antagonizes the Y5 receptor.

51. The method of Claim 50 wherein the Y5 mediated disease is obesity.

52. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of claim 26.